Telomere Extension Reverses Biological Age by 12 Years
Gene therapy trials successfully extend telomeres in aged cells, reversing key aging markers.
1The Science of Aging
In a result that has sent shockwaves through the gerontology community, a gene therapy trial has demonstrated that targeted telomere extension can reverse biological age by an average of 12 years as measured by epigenetic clocks .
2Telomere Extension Results
The therapy uses an AAV vector to deliver a modified TERT gene — the enzyme responsible for maintaining telomere length — directly to multiple tissue types . After a single treatment, participants showed progressive telomere lengthening over 12 months, with corresponding improvements in multiple biomarkers of aging.
3Biomarker Reversal
Treated participants showed significant improvements in grip strength (+18%), VO2 max (+14%), skin elasticity (+22%), and cognitive processing speed (+11%) compared to placebo . Epigenetic clock analysis using the Horvath and GrimAge algorithms confirmed a mean biological age reduction of 12.3 years.
4Ethical Considerations
The trial raises profound ethical questions about access, equity, and the societal implications of significantly extending healthy lifespan. The research team has partnered with bioethicists to develop a framework for responsible clinical translation .
- 12-year average reversal in biological age
- AAV-delivered modified TERT gene therapy
- 18% improvement in grip strength, 14% in VO2 max
- Confirmed by Horvath and GrimAge epigenetic clocks
- Single treatment with progressive 12-month improvement
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Aging.
In This Article
Related Conditions
Active Clinical Trials
Phase III: Longevity Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
12,340 consumers have expressed interest in this topic. Researchers studying Aging can see anonymized demand signals.
Telomere Extension Reverses Biological Age by 12 Years
Gene therapy trials successfully extend telomeres in aged cells, reversing key aging markers.
1The Science of Aging
In a result that has sent shockwaves through the gerontology community, a gene therapy trial has demonstrated that targeted telomere extension can reverse biological age by an average of 12 years as measured by epigenetic clocks .
2Telomere Extension Results
The therapy uses an AAV vector to deliver a modified TERT gene — the enzyme responsible for maintaining telomere length — directly to multiple tissue types . After a single treatment, participants showed progressive telomere lengthening over 12 months, with corresponding improvements in multiple biomarkers of aging.
3Biomarker Reversal
Treated participants showed significant improvements in grip strength (+18%), VO2 max (+14%), skin elasticity (+22%), and cognitive processing speed (+11%) compared to placebo . Epigenetic clock analysis using the Horvath and GrimAge algorithms confirmed a mean biological age reduction of 12.3 years.
4Ethical Considerations
The trial raises profound ethical questions about access, equity, and the societal implications of significantly extending healthy lifespan. The research team has partnered with bioethicists to develop a framework for responsible clinical translation .
- 12-year average reversal in biological age
- AAV-delivered modified TERT gene therapy
- 18% improvement in grip strength, 14% in VO2 max
- Confirmed by Horvath and GrimAge epigenetic clocks
- Single treatment with progressive 12-month improvement
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Aging.
In This Article
Related Conditions
Active Clinical Trials
Phase III: Longevity Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
12,340 consumers have expressed interest in this topic. Researchers studying Aging can see anonymized demand signals.